Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mangoceuticals (MGRX) Gross Margin (2023 - 2025)

Mangoceuticals' Gross Margin history spans 3 years, with the latest figure at 50.31% for Q4 2025.

  • On a quarterly basis, Gross Margin fell 2580.0% to 50.31% in Q4 2025 year-over-year; TTM through Dec 2025 was 54.91%, a 679.0% decrease, with the full-year FY2025 number at 54.91%, down 679.0% from a year prior.
  • Gross Margin hit 50.31% in Q4 2025 for Mangoceuticals, down from 60.42% in the prior quarter.
  • Over the last five years, Gross Margin for MGRX hit a ceiling of 76.11% in Q4 2024 and a floor of 42.77% in Q2 2024.
  • Historically, Gross Margin has averaged 58.88% across 3 years, with a median of 58.66% in 2023.
  • Biggest five-year swings in Gross Margin: skyrocketed 1776bps in 2024 and later crashed -2580bps in 2025.
  • Tracing MGRX's Gross Margin over 3 years: stood at 58.35% in 2023, then soared by 30bps to 76.11% in 2024, then tumbled by -34bps to 50.31% in 2025.
  • Business Quant data shows Gross Margin for MGRX at 50.31% in Q4 2025, 60.42% in Q3 2025, and 53.51% in Q2 2025.